CoChat

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany

Open access
Menzen, Markus, Berentzen, Tina Landsvig, Catarig, Andrei-Mircea, Pieperhoff, Sebastian, Simon, Jörg, Jacob, Stephan · 2023 · Experimental and Clinical Endocrinology & Diabetes

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Context Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care. It is useful to complement these findings with real-world evidence. Objective SURE Germany evaluated once-weekly semaglutide in a real-world type 2 diabetes patient population. Design/setting The prospective observational study was conducted at 93 clinical practices in adults with+≥ 1 documented glycated haemoglobin value ≤12 weeks before initiation of semaglutide. Intervention Once-weekly semaglutide was prescribed at the physicians’ discretion. Main outcomes The primary endpoint was change in glycated haemoglobin from baseline to end-of-study (~30 weeks). Secondary endpoints included changes in body weight and patient-reported outcomes. All adverse events were systematically collected and reported, including patient-reported documented and/or severe hypoglycaemia. Results Of 779 patients in the full analysis set, 669 (85.9%) completed the study on treatment with semaglutide, comprising the effectiveness analysis set. In this data set, estimated mean changes in glycated haemoglobin and body weight from baseline to end-of-study were –1.0%point (–10.9 mmol/mol; P<0.0001) and –4.5 kg (–4.2%; P<0.0001). Sensitivity analyses supported the primary analysis. Improvements were observed in other secondary endpoints, including patient-reported outcomes. No new safety concerns were identified. Conclusions In a real-world population in Germany, patients with type 2 diabetes treated with once-weekly semaglutide experienced clinically significant improvements in glycaemic control and body weight. These results support the use of once-weekly semaglutide in routine clinical practice in adult patients with type 2 diabetes in Germany.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/a-2007-2061

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Patient disposition. Abbreviations: EOS: end of study; GI: gastrointestinal. *Patients who initiated the semaglutide treatment and attended the EOS visit.
Fig. 1 Patient disposition. Abbreviations: EOS: end of study; GI: gastrointestinal. *Patients who initiated the semaglutide treatment and attended the EOS visit.CC BY-NC-ND · PubMed Central
Fig. 2 Proportions of patients achieving prespecified targets at EOS (total and by medication subgroup from the EAS): ( a ) HbA 1c targets of <8.0%, < 7.5%, <7.0%, and≥1.0%-point reduction, ( b ) weight-loss responses of≥3% and≥5%, ( c ) composite endpoint of HbA 1c reduction≥1%-point and weight loss≥3%. Abbreviations: EAS: effectiveness analysis study; EOS: end of study; GLP-1RA: glucagon-like peptide-1 receptor agonist; OAD: oral antihyperglycaemic drug; GI: gastrointestinal; N: number of patients; NA: not applicable; SADR: serious adverse drug reaction.
Fig. 2 Proportions of patients achieving prespecified targets at EOS (total and by medication subgroup from the EAS): ( a ) HbA 1c targets of <8.0%, < 7.5%, <7.0%, and≥1.0%-point reduction, ( b ) weight-loss responses of≥3% and≥5%, ( c ) composite endpoint of HbA 1c reduction≥1%-point and weight loss≥3%. Abbreviations: EAS: effectiveness analysis study; EOS: end of study; GLP-1RA: glucagon-like peptide-1 receptor agonist; OAD: oral antihyperglycaemic drug; GI: gastrointestinal; N: number of patients; NA: not applicable; SADR: serious adverse drug reaction.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 29

Metadata

Authors
Menzen, M., Berentzen, T. L., Catarig, A.-M., Pieperhoff, S., Simon, J., & Jacob, S.
Affiliations
  • Gemeinschaftskrankenhaus Bonn, Innere Medizin – Diabetologie und Endokrinologie, Bonn, Germany
  • Novo Nordisk (Denmark) (DK)
  • Novo Nordisk (Germany) (DE)
  • MVZ im Altstadt-Carree Fulda GmbH, Fulda, Germany
  • Cardio-metabolic Institute, Villingen, Germany
Corresponding author
Menzen, Markus
Venue
Experimental and Clinical Endocrinology & Diabetes
Published
2023-01-04
Volume
131
Issue
04
Pages
205-215
ISSN
  • 0947-7349 (ISSN-L)
  • 1439-3646
OpenAlex
W4313490144
Cited by
29
References
28
Citations by year
2026: 6 · 2025: 5 · 2024: 11 · 2023: 7
FWCI
5.91
Type
journal article
Language
en
Open access
Locations
  • Experimental and Clinical Endocrinology & Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Novo Nordisk (NA)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, type 2 diabetes, HbA1c, glycemic control, weight loss, patient-reported outcomes, hypoglycemia, adverse events, real-world effectiveness, GLP-1 receptor agonists, clinical practice
MeSH terms
Semaglutide, Adult, Body Weight, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany. https://app.cochat.ai/papers/10.1055/a-2007-2061
The paper
Menzen, M., Berentzen, T. L., Catarig, A.-M., Pieperhoff, S., Simon, J., & Jacob, S. (2023). Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany. Experimental and Clinical Endocrinology & Diabetes. https://doi.org/10.1055/a-2007-2061

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.